Last checked at 12 Aug 2014 07:35
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Scancell Holdings Share News (SCLP)
SCLP Share
Price
SCLP Share
News
SCLP Share
Chat3
SCLP Share
Trades18
SCLP
Live RNS
SCLP Share
Charts
SCLP Level 2
Console
SCLP Live
Share Price
SCLP Broker
Ratings
SCLP Directors
Deals
SCLP Financial
Diary
SCLP
Fundamentals
SCLP Short
Positions
SCLP
Media
Scancell Holdings Information
Share Price Information for Scancell Holdings (SCLP)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
10.25
Bid:
10.00
Ask:
10.50
Change:
0.00 (0.00%)
Spread:
0.50 (5.00%)
Open:
10.25
High:
10.50
Low:
10.25
Prev. Close:
10.25
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.Prezzo exec slices off 200,000 shares
Tue, 22nd Oct 2013 16:26
Kuldip Sehmi, an Executive Director at Italian restaurant chain Prezzo, on Monday traded in 200,000 shares, reducing his stake to 682,244 shares, equal to 0.29 per cent of the issued share capital. Sehmi, who is responsible for the day to day running of approximately half the Prezzo estate, sold the shares at 117p each for a total trade value of £234,000. While significant, the size of the transaction pales in comparison to that made by Jonathan Kaye, the group's Chief Executive Officer, and two of its Non-Executive Directors, last month, when they each traded in a 1.3m share slice of the company. At the beginning of September, the group posted a 17% leap in half year revenue to £79.7m, while adjusted pre-tax profit climbed 12% to £8.5m, and said it was "confident of delivering a satisfactory outcome for the year as a whole".Top Director BuysAberforth Geared Income Trust (AGIT) Director name: Mr Graham R MenziesAmount purchased: 49,865 @ 158.12p Value: £78,847JPMorgan European Inv Trust Growth Shares (JETG) Director name: Mr Andrew AdcockAmount purchased: 25,000 @ 217.50p Value: £54,375STV Group (STVG) Director name: Mr Genevieve Shore Amount purchased: 5,564 @ 264.75p Value: £14,731Top Director SellsGLOBO (GBO) Director name: Mr Gavin BurnellAmount sold: 505,000 @ 71.00p Value: £358,550Prezzo (PRZ) Director name: Mr Kuldip SehmiAmount sold: 200,000 @ 117.00p Value: £234,000GLOBO (GBO) Director name: Mr Gerasimos (Makis) BonanosAmount sold: 250,000 @ 71.00p Value: £177,500GLOBO (GBO) Director name: Mr Dimitrios GryparisAmount sold: 245,000 @ 71.00p Value: £173,950Dairy Farm International Holdings Ltd. (Singapore) (DFI) Director name: Mr Michael KokAmount sold: 13,500 @ $11.13 Value: $150,246Dillistone Group (DSG) Director name: Mr Giles Robin Fearnley Amount sold: 150,000 @ 100.10p Value: £150,150Scancell Holdings (SCLP) Director name: Dr Richard GoodfellowAmount sold: 100,000 @ 30.00p Value: £30,000Scancell Holdings (SCLP) Director name: Professor Lindy DurrantAmount sold: 100,000 @ 30.00p Value: £30,000Dunedin Enterprise Investment Trust (DNE) Director name: Mr Liz AireyAmount sold: 2,500 @ 475.00p Value: £11,875
More News
6 Jun 2014 08:54
Scancell Holdings ImmunoBody technology receives US approval
AIM-listed Pharmaceuticals group Scancell Holdings announced a patent for its DNA ImmunoBody technology has been approved in the US. The patent has been granted by the United States Patent and Trademark Office (USPTO) and covers Scancell's DNA ImmunoBody platform technology. This patent is expect
Read more6 Jun 2014 08:52
Scancell Granted US Patent For DNA Immunobody Technology
LONDON (Alliance News) - Scancell Holdings PLC said Friday its DNA Immunobody technology platform had been granted a patent by the US Patent and Trademark Office. Scancell said the patent was key for the protection of its pipeline of vaccines utilising the technology. It has already been gr
Read more2 Jun 2014 11:08
Scancell reports encouraging results of melanoma treatment
Scancell's shares advanced after announcing "encouraging results" from the clinical trial of its SCIB1 ImmunoBody drug for the treatment of stage III/IV melanoma. The phase 1 and 2 trial tested the safety and tolerability of four dose levels of SCIB1 administered intramuscularly using an electropo
Read more2 Jun 2014 10:39
UK WINNERS & LOSERS: Miners Jump On Upbeat Chinese Data
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Monday.
-------
FTSE 100 - WINNERS
-------
Anglo American, up 1.9%, Rio Tinto, up 1.7%, Glencore, up 1.4
2 Jun 2014 08:04
Scancell Rises As It Gets More Good Results From Skin Cancer Treatment Trial
LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Monday after it said the latest results from a trial of its SCIB1 ImmunoBodyÒ treatment on skin cancer had shown further evidence of tumour reduction and disease control, enhanced immune responses and "h
Read more27 May 2014 12:47
Oxford Technology NAV Declines, Appealing VCT Status Withdrawal
LONDON (Alliance News) - Oxford Technology VCT PLC saw its net asset value per share decline in the year to end-February, and said it was appealing the withdrawal of its venture capital trust status. The trust posted a net asset value per share of 65 pence per share, down from 74 pence in t
Read more15 May 2014 12:46
Scancell Holdings To Present Phase I/II ImmunoBody Trial Data At ASCO
LONDON (Alliance News) - Scancell Holdings PLC said Thursday that it will announce the latest data from its ongoing Phase I/II clinical trial of its SCIB1 ImmunoBody treatment for stage III/IV melanoma will be presented at the American Society of Clinical Oncology meeting in Chicago at the end of
Read more1 May 2014 13:03
UK MIDDAY BRIEFING: Lloyds Kicks Off Bank Season With Improvement
LONDON (Alliance News) - Lloyds Banking Group kicked off the first-quarter bank earnings season Thursday, reporting that its pretax profit dropped by a third to GBP1.37 billion after last year was buoyed by gains on the sale of government securities.
However, its un
1 May 2014 11:27
UK WINNERS & LOSERS: Lloyds Atop FTSE 100 Risers; Weir Leads Fallers
LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices midday Thursday.
-------
FTSE 100 - WINNERS
-------
Lloyds Banking Group, up 4.8%. The banking group is the biggest riser in the
1 May 2014 10:29
Scancell Rises As Long-Time Consultant Joins Its Board
LONDON (Alliance News) - Cancer treatment developer Scancell Holdings PLC saw its shares rise Thursday after it appointed long-time consultant Dr Sally Adams to its board as development director with immediate effect. In a statement, the company, which is developing immunotherapies to treat
Read more4 Apr 2014 09:55
Scancell To Announce Phase I/II Of Melanoma Clinical Trial On April 8
LONDON (Alliance News) - Scancell Holdings PLC Friday said that it will announce the results of phase one and two of its clinical trial in patients with stage three and four melanoma at the American Association for Cancer Research annual meeting in San Diego next Tuesday. Scancell Holdings
Read more21 Mar 2014 09:11
Scancell Holdings Completes Phase 1 Of Melanoma Clinical Trial
LONDON (Alliance News) - Scancell Holdings PLC Friday said it has completed patient dosing with 8mg of SCIB1 ImmunoBody in part one of its on-going phase 1/2 clinical trial in patients with Stage III/IV melanoma. The trial followed a study the firm conducted which showed that a 4mg dose of
Read more18 Feb 2014 09:19
Scancell Says Patent Application For Cancer Fighting Platform Published
LONDON (Alliance News) - Scancell Holdings PLC Tuesday said its patent application for Moditope has been published, with a view to guarding the platform until 2033 once the patent is granted. In a statement, Scancell said the application for the Modicope platform describes how it uses certa
Read more11 Feb 2014 09:50
Scancell Gets US Orphan Drug Tag For Metastatic Melanoma Treatment
LONDON (Alliance News) - Scancell Holdings PLC said Tuesday its SCIB1 ImmunoBody metastatic melanoma treatment had been granted orphan drug designation by the US Food and Drug Administration. This designation means that Scancell can qualify for a 50% tax credit for clinical trials of the tr
Read more